High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
about
Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem"Marine-derived anticancer agents in clinical trials.Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.New developments in treatment of ovarian carcinoma: focus on trabectedinRole of trabectedin in the treatment of soft tissue sarcomaPreclinical and clinical results with the natural marine product ET-743.Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsPhase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Trabectedin: novel insights in the treatment of advanced sarcoma.Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effectsGene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.Trabectedin is a promising antitumour agent for synovial sarcoma.A novel polypeptide from Meretrix meretrix Linnaeus inhibits the growth of human lung adenocarcinoma.Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.Mode of action of trabectedin in myxoid liposarcomas.A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
P2860
Q26746924-FEF7F39E-3CE7-4948-9CE5-9FDB2BE601E4Q30969641-3BE9C908-28BE-49BD-BEE1-B2AED49BB86FQ33392364-C108F4F4-5E39-4107-9EBB-C49FCAAB4C96Q33393429-DCDA5ADE-512E-47ED-81F6-8FF9B5FE995FQ33916011-66D44D55-F73E-404B-A4DA-7C51419B56FAQ34542908-7C6F12AE-7A2D-4758-9E7D-4831966CD419Q34898364-F247703A-1E91-4FE6-82E7-D877AEB069D5Q35676502-2BF7E854-F7F9-415B-939F-C2AE853F9BAAQ36567662-83A4D736-27B2-465B-AB63-28621551C621Q36610752-41F43BDE-67BA-4FE4-8C8E-DAECFE9FFDDAQ36895793-7ABC47C5-5584-4BE4-9A42-6FDCBDC7994BQ37005569-C30A7387-56FF-4014-AF13-0CFB3CA85C13Q37760957-C736283D-C2AD-41FF-BC8E-CBD15539FB05Q37765581-01536C15-7A8A-4963-A294-1EB49EF0F837Q37809986-E3A8C4A0-9801-4C62-B07A-85127D557563Q37969213-E1852793-3C62-4C54-B812-6D4D6AB92794Q38206396-C38D3CC9-2564-4593-B444-E94C536BC253Q38255906-10477BED-3CDC-4C7F-BE1E-834C7B788D51Q38611141-C5375CC1-AD51-45AB-B4DC-B346D3989DF7Q38728270-0D7A97A5-4170-4628-A625-F14E673C2513Q38778290-9B5BAF0D-B5ED-4201-87AB-F28AA3484CACQ39361167-DD571168-CBF0-42FF-8963-B02A8BB446ABQ39497253-B8CFC73E-B5F2-4FDA-AD73-4B59891DE530Q41712411-DC41ED21-9BDB-4BEC-A8BD-29AA8E2EEAB2Q44116130-DCA4FC60-CAAC-48B2-81FD-52B7F9DE84C2Q45346605-B7B5E164-52B3-404F-AFC6-E54D373F4903Q57570787-3625998F-0CCC-487C-BD5D-40B2181A3B84
P2860
High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@ast
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@en
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@nl
type
label
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@ast
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@en
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@nl
prefLabel
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@ast
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@en
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@nl
P2093
P356
P1433
P1476
High antitumour activity of ET ...... -cell lung and ovarian cancer.
@en
P2093
G T Faircloth
H H Fiebig
H R Hendriks
J M Jimeno
S P Langdon
P304
P356
10.1023/A:1008364727071
P577
1999-10-01T00:00:00Z